BABAM2 and esophageal squamous cell carcinoma: Moreover, by treating BRE-overexpressed ESCC cells with an AKT inhibitor, we further confirmed that AKT signaling was required for cell growth and apoptotic resistance in BRE-overexpressing cells, which is consistent with studies reporting that AKT potently promotes ESCC cell progression and patient survival (29, 30).